TULSA-PRO bets on RCT functional superiority over robotic prostatectomy driving reimbursement and adoption; 3-year oncologic data will confirm or undercut the durable value claim

Bull

A positive outcome would show high rates of negative 12-month biopsy (absence of clinically significant residual or recurrent disease) and favorable MRI findings in the TULSA arm, consistent with complete or near-complete ablation, alongside continued absence of additional treatment initiation. This would validate the oncologic durability premise, provide a compelling data package to support payer coverage expansions beyond Humana, and meaningfully de-risk the 3-year freedom-from-treatment primary endpoint, catalyzing further installed base growth and reimbursement negotiations.

Bear

A disappointing outcome would manifest as elevated rates of positive 12-month biopsies or MRI evidence of residual disease in the TULSA arm, suggesting incomplete tumor control in Gleason Score 7 intermediate-risk disease. The most likely failure modes are undertreated peripheral zone disease given the transurethral delivery geometry, or upstaged pathology at baseline that was not captured pre-randomization; either would raise durable concerns about whether ablation can match the disease-control benchmark set by robotic prostatectomy and would undermine the reimbursement and guideline-inclusion arguments.